Cognition Disorders, Fatigue Syndrome, Chronic, Hepatitis C, Chronic, Major Depressive Disorder
Conditions
Keywords
Chronic Hepatitis C, cognitive dysfunction, MRI, MR spectroscopy, interferon, ribavirin, sustained virologic response, major depressive disorder
Brief summary
Patients with HCV infection often suffer from chronic fatigue, depression and reduced cognition, even before evolving severe liver fibrosis, liver cirrhosis and hepatic encephalopathy. It is currently unclear to what extent the symptoms er due to a direct pathological effects of the virus itself, or due to pre-existing psychiatric disease. There is a complex relationship between prior or existing drug abuse, psychiatric disease and HCV infection, that makes it difficult to establish cause-effect relationships. A biological mechanism has been suggested to contribute to development of cerebral dysfunction in the patients. According to the prevailing Trojan Horses hypothesis circulating lymphocytes cross the blood brain barrier carrying HCV to the central nervous system and virus is subsequently replicated in the macrophages and the microglia in brain as a separate compartment. As part of the immunological response to viral replication, neurodegenerative processes takes place with a harmful effect on the neural circuit and cerebral function. Identification of HCV RNA negative strand, a replication product, in brain tissue from HCV patients, as part of autopsy studies, supports the hypothesis. Moreover, HCV patients have also been observed with abnormal metabolic concentrations in the frontal white substance and the basal ganglia by MRI spectroscopy compared to control groups. The overall study objective is to assess cerebral function with particular emphasis on cognitive functions in HCV patients (genotypes 1,2,3 and 4) by use of a neuropsychiatric test battery. Furthermore, the patients will be examined by MRI, including magnetization transfer, diffusion tensor and contrast perfusion, in order to perform measurements of cerebral volumetric and microstructure. Finally, HCV analysis, including viral sequences and cytokine profiles, in serum and cerebrospinal fluid will be carried out in the study population.
Interventions
DRUGInterferon and ribavirin
Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
Sponsors
Aarhus University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Chronic HCV infection with genotype 1, 2, 3 or 4. * Age \> 18 and \<60 * Liver biopsy or fibroscan performed within last 5 years * Signed informed consent form.
Exclusion criteria
* Liver biopsy showing liver pathology not due to HCV infection. * Liver cirrhosis or severe liver fibrosis * Former antiviral HCV treatment (for included HCV patients). * HIV and/or Hepatitis B virus infection. * Alcohol or drug abuse within the last 2 years. * Neutropenia, anemia or thrombocytopenia. * Clinical signs of non-compensated liver pathology. * Moderate to severe cardiopulmonary disease (NYHA score 1 or above) * Creatinine clearance \< 80mL/min. * Pregnancy. * Ferromagnetic implants * Significant somatic disease affecting the central nervous system (somatic/neurologic disease) * Head trauma resulting in unconsciousness \> 5min * Schizophrenia or other psychotic disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neuropsychological test results, cytokine profile and MRI findings | 8 weeks before starting IFN+RIB therapy | Assessment performed before starting antiviral treatment in patients with chronic hepatitis C who awaits treatment. HCV patients without pending treatment will be tested in conjunction with their outpatient controls. |
Secondary
| Measure | Time frame |
|---|---|
| Interferon-induced depression | 8-12 weeks after treatment inititation |
Countries
Denmark
Outcome results
None listed